Evidence map›Paper›PMID 36553594›Full record

SynthesisGenes2022

Clinical Investigation of Chemotherapeutic Resistance and miRNA Expressions in Head and Neck Cancers: A Thorough PRISMA Compliant Systematic Review and Comprehensive Meta-Analysis.

Rama Jayaraj, Karthikbinu Polpaya, Milind Kunale, Gothandam Kodiveri Muthukaliannan, Sameep Shetty, Siddhartha Baxi, Ravishankar Ram Mani, Chitraabaanu Paranjothy, Vinosh Purushothaman, Saminathan Kayarohanam and 2 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. New evidence for miRNA testing in head and neck squamous cell cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Rama JayarajJindal Institute of Behavioral Sciences (JIBS), Jindal Global Institution of Eminence Deemed to Be University, Sonipat 131001, India.ORCID 0000-0002-2179-0510
Karthikbinu PolpayaSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore 632014, India.
Milind KunaleSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore 632014, India.ORCID 0000-0002-2455-4775
Gothandam Kodiveri MuthukaliannanSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore 632014, India.ORCID 0000-0003-1576-5324
Sameep ShettyDepartment of Oral and Maxillofacial Surgery, Manipal College of Dental Sciences, Mangalore, Manipal Academy of Higher Education, A Constituent of MAHE, Manipal 576104, India.
Siddhartha BaxiMBBS, FRANZCR GAICD (Siddhartha Baxi), Genesis Care Gold Coast Radiation Oncologist, Tugun, QLD 4224, Australia.ORCID 0000-0002-6207-1942
Ravishankar Ram ManiDepartment of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, UCSI University Kuala Lumpur (South Wing), No. 1, Jalan Menara Gading, UCSI Heights Cheras, Kuala Lumpur 56000, Malaysia.ORCID 0000-0003-4229-5778
Chitraabaanu ParanjothyDepartment of Health, University of Essex, Leeds LS1 2RP, UK.
Vinosh PurushothamanFaculty of Health and Life Sciences, INTI International University, Nilai 71800, Malaysia.
Saminathan KayarohanamFaculty of Bioeconomics and Health Sciences, University Geomatika Malaysia, Kuala Lumpur 54200, Malaysia.
Ashok Kumar JanakiramanDepartment of Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, UCSI University Kuala Lumpur (South Wing), No. 1, Jalan Menara Gading, UCSI Heights Cheras, Kuala Lumpur 56000, Malaysia.ORCID 0000-0002-9670-8323
Ashok Kumar BalaramanFaculty of Pharmacy, MAHSA University, Bandar Saujana Putra, Jenjarom 42610, Malaysia.ORCID 0000-0002-5121-5170
Vellore Institute of Technology University · INUCSI University · MYINTI International University · MYMahsa University · MYManipal Academy of Higher Education · INNorthern Territory Health Services · AUUniversity of Essex · GB

Funding

Enhancing immune mediated head and neck cancer anti-tumor activity using nanoparticlesR01DE028105 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KRISHNAN, SUNIL, SKINNER, HEATH DEVIN · 2019 to 2023
$2.4M
NIDCR NIH HHS R01 DE028105
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Head and Neck NeoplasmsMicroRNAsBiomarkers, TumorHumansPrognosisBiomarkers, TumorMicroRNAsMIRN145 microRNA, humanchemoresistancedown-regulationhazard ratiohead and neck cancer (HNC)miRNApatient survivalPRISMAprognosisprotocolsystematic reviewup-regulation

Identifiers

PMID36553594
PMCPMC9777665
OpenAlexW4312125669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.